Prostate Cancer

The introduction of 2 therapies for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)—the orally administered abiraterone acetate (Zytiga) and enzalutamide (Xtandi)—has prompt­­ed Leslie Hazel-Fernandez, PhD, Comprehensive Health Insights, Louisville, KY, and colleagues to conduct a qualitative study to evaluate the personal and other factors that influence the use of oral drugs among patients with mCRPC, as well as to gauge caregivers’ and physicians’ experiences with patients who use these oral medications. Read More ›

Adding docetaxel (Taxotere) to standard hormone therapy extends overall survival (OS) by a median of 10 months versus hormone therapy alone in men with newly diagnosed, advanced, hormone therapy–naïve prostate cancer, according to the results of the STAMPEDE trial. Read More ›

Enzalutamide (Xtandi) outperformed bicalutamide (Casodex) in 2 separate phase 2 clinical trials of men with prostate cancer, according to data presented at the 2015 American Urological Association annual meeting. Read More ›

Updated NCCN Guideline for Prostate Cancer Allows Early Treatment with Docetaxel
Early use of docetaxel in some men with castration-resistant prostate cancer was associated with a 17-month improvement in survival, according to new data supporting the updated NCCN guideline. Read More ›

Programs Raise Awareness of Risks Associated with Testosterone Replacement Therapy
Two pilot programs that bridge health plans and health systems showed success in raising awareness of inappropriate testosterone replacement therapy in men with age-related hypogonadism. Read More ›

n analysis using the IMS LifeLink Health Plan Claims Database has shown that patients who undergo minimally invasive robotic-assisted radical prostatectomy experience a shorter hospital length of stay and somewhat better postoperative outcomes than patients who undergo open radical prostatectomy, albeit with a higher price tag, according to a study that was published recently in Prostate Cancer and Prostatic Disease. Read More ›

Significant cost-savings in treating patients with prostate cancer could be achieved in the US healthcare system with the use of the cell-cycle progression (CCP) gene-expression assay called Prolaris. Read More ›

A novel gene panel is showing promise for determining which treatment-naïve patients with prostate cancer could benefit from intensified treatment. Read More ›

In men with prostate cancer undergoing curative radiation therapy, it may be possible to preserve sexual function by using a vessel-sparing radiation technique, according to the 5-year follow-up results from a study of men who underwent vessel-sparing radiation therapy in this setting. Read More ›

Anew guideline for systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC) is based on a literature review of recent publications and outlines the survival and quality-of-life benefits/toxicity effects of each recommendation. Read More ›

Page 4 of 5

Urology Practice Management logo
Subscribe to Urology Practice Management

Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.

UPM e-Newsletter
UPM print publication